Viva Biotech Highlights AI and Flow Chemistry Integration for Scalable Drug Synthesis
Viva Biotech hosted a webinar titled "AI x Flow Chemistry: From Bench to Business" to explore how artificial intelligence and flow chemistry are shaping modern synthesis workflows, announced in a press release. The event featured academic and industry experts discussing how these technologies are bridging the gap between molecular design and scalable execution.
Professor Jie Wu from the National University of Singapore presented advances in automated multistep synthesis, emphasizing the use of high speed circulation flow systems that combine batch and continuous processing. He introduced Chemical Recipe Files as a method to encode optimized synthesis protocols in a reproducible, machine executable format, supporting automated and scalable workflows.
Dr. Kejia Ding from Viva Biotech described how flow chemistry is being deployed across medicinal chemistry, process development, and manufacturing. Case studies included photochemical and difluoromethyl syntheses, where flow processing improved safety and scalability. A subsidiary, Langhua Pharma, demonstrated a continuous flow Curtius rearrangement that produced one thousand kilograms of material within two months.
The discussion highlighted how combining AI with automated synthesis and flow chemistry enables faster experimental validation of digitally designed molecules. Viva Biotech’s integrated platform connects discovery, synthesis, and manufacturing capabilities to support partners from early research through production.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Veeva to Showcase Falcon and Vault AI at Boston Summit
Tsingke Introduces Validation Workflow for AI Designed Proteins
Flow Engineering Raises $50 Million at $750 Million Valuation
AbbVie Partners With Valkai on AI Tools for Clinical Development
ACROBiosystems Launches ACRO AIx and Rapid Antibody Validation Service
Daily AI Brief: the AI news that matters, in your inbox.